Nurden A T
UMR 5533 CNRS, Hôpital Cardiologique, Pessac, France.
Haemostasis. 1996 Oct;26 Suppl 4:78-88. doi: 10.1159/000217288.
Platelets play a key role in arterial thrombosis. Inhibition of platelet function forms an essential part of anti-thrombotic therapy. Although aspirin is a cost-effective drug which offers considerable scope in the prevention of arterial thrombosis, it only inhibits part of the platelet activation process. Much recent progress has concerned the inhibition of surface receptors of platelets. Ticlopidine and clopidogrel specifically interfere with the ADP-induced activation pathway. Inhibitors of GP IIb-IIIa complexes, including c7E3, block the final step of the platelet aggregation process as used by all physiologic agonists and are proving powerful therapeutic agents. This review looks at these and future advances in the construction of therapeutic strategies aimed at combatting arterial thrombosis.
血小板在动脉血栓形成中起着关键作用。抑制血小板功能是抗血栓治疗的重要组成部分。尽管阿司匹林是一种具有成本效益的药物，在预防动脉血栓形成方面有很大作用，但它仅抑制血小板激活过程的一部分。最近在抑制血小板表面受体方面取得了很大进展。噻氯匹定和氯吡格雷特异性干扰ADP诱导的激活途径。包括c7E3在内的糖蛋白IIb-IIIa复合物抑制剂可阻断所有生理激动剂所使用的血小板聚集过程的最后一步，并且已被证明是强大的治疗药物。本文综述了这些以及旨在对抗动脉血栓形成的治疗策略构建方面的未来进展。
